2026-04-17T00:50:12Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1775582025-12-05T12:18:47Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Ferrer, Ferran author Pont, Àngels author Blas, Rodolfo de author Boladeras, Anna author Garin, O. author Ventura, Montse author Zardoya, Eva author Delgado, J. author Condom, E. author Merino Cabrera, Esperanza author Mases, Joel author Castells-Esteve, Manel author Guix, Inés author Suárez-Novo, José Francisco author Gonzalez, Javier author Almendros, Sonia author Garcia, M. author Berenguer, Miguel Ángel author Garcia, N. author Stefanovic, M. author Gutierrez, Cristina author Picon, Cristina author Ferrer, Montserrat author Guedea Edo, Ferran author 2021-05-25T07:25:16Z 2021-05-25T07:25:16Z 2019-04-01 2021-03-10T14:05:31Z Purpose or ObjectiveExtracranial stereotactic body radiation therapy (SBRT) allows delivering high doses per fraction with high accuracy to the prostatic gland in a low number of fractions.Dose escalation in normofractionaded radiation prostate cancer trials showed an increased toxicity.In order to evaluate the feasibility and toxicity of a regimen of a single dose hypofractionated prostate stereotactic boost a phase II study was undertaken. Self-reported quality of life (QOL) measures were also obtained in order to better define the possible deleterious effect of treatment. Radioteràpia Càncer de pròstata Radiotherapy Prostate cancer Early experience and quality of life in SBRT prostate cancer boost of 9 Gy in a phase II trial